Custom Recombinant Antibody Conversion Service Market Will Reach New Heights in the Upcoming Year 2023-2030 - openPR
GNNSF Stock | USD 1.44 0.03 2.13% |
Roughly 55% of Genscript Biotech's stockholders are presently thinking to get in. The analysis of overall sentiment of trading Genscript Biotech pink sheet suggests that some investors are interested at this time. The current market sentiment, together with Genscript Biotech's historical and current headlines, can help investors time the market. In addition, many technical investors use Genscript Biotech stock news signals to limit their universe of possible portfolio assets.
Genscript Biotech pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Genscript daily returns and investor perception about the current price of Genscript Biotech as well as its diversification or hedging effects on your existing portfolios.
Genscript |
Custom Recombinant Antibody Conversion Service Market Will Reach New Heights in the Upcoming Year 2023-2030 openPR
Read at news.google.com
![]() |
Genscript Biotech Fundamental Analysis
We analyze Genscript Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genscript Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genscript Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Genscript Biotech is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Genscript Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genscript Biotech pink sheet to make a market-neutral strategy. Peer analysis of Genscript Biotech could also be used in its relative valuation, which is a method of valuing Genscript Biotech by comparing valuation metrics with similar companies.
Peers
Genscript Biotech Related Equities
ONTTF | Oxford Nanopore | 16.24 | ||||
LCTX | Lineage Cell | 1.92 | ||||
MRUS | Merus BV | 1.48 | ||||
CRNX | Crinetics Pharmaceuticals | 1.41 | ||||
IVBXF | Innovent Biologics | 0.98 | ||||
TLPPF | Telix Pharmaceuticals | 0.71 | ||||
KRON | Kronos Bio | 1.04 | ||||
NXTC | NextCure | 1.33 | ||||
ZNTL | Zentalis Pharmaceuticals | 1.65 | ||||
INBX | Inhibrx | 3.46 | ||||
KROS | Keros Therapeutics | 4.04 | ||||
ICCC | ImmuCell | 4.70 | ||||
NUVL | Nuvalent | 5.19 | ||||
OVID | Ovid Therapeutics | 5.77 | ||||
CNTB | Connect Biopharma | 5.88 | ||||
NUVB | Nuvation Bio | 6.93 | ||||
LYEL | Lyell Immunopharma | 8.11 | ||||
CVKD | Cadrenal Therapeutics, | 8.49 |
Complementary Tools for Genscript Pink Sheet analysis
When running Genscript Biotech's price analysis, check to measure Genscript Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genscript Biotech is operating at the current time. Most of Genscript Biotech's value examination focuses on studying past and present price action to predict the probability of Genscript Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genscript Biotech's price. Additionally, you may evaluate how the addition of Genscript Biotech to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |